Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Antimicrobial Resistance

    $67.2M Next-Generation Antibiotic Contract Awarded

    By Stephanie LizotteJanuary 30, 2012
    Drug Development for Biodefense
    Share
    Facebook LinkedIn Reddit Email

    CUBRC, Inc. and Tetraphase Pharmaceuticals have been awarded a contract for the advanced development of an antibiotic (TP-434) that could potentially treat illnesses caused by biological threats such as anthrax, plague, bacterial pneumonia and certain life-threatening bacterial infections associated with prolonged hospitalization.

    The Biomedical Advanced Research and Development Authority (BARDA) will support and manage the contract, which is worth $11.4 million in year one.  The contract can be extended to a total of five years, worth $67.2 million in the end.

    TP-434 currently being developed by Tetraphase Pharmaceuticals is a tetracycline class of antibiotic, which treats intra-abdominal infections.  Early indications lead to the possibility that TP-434 could be effective against many antibiotic resistant bacteria.  The contract will support testing of TP-434 in clinical and animal studies and in improving drug manufacturing.  The development of both oral and intravenous formulations of TP-434 is supported.

    TP-434 is the fourth to be funded under the Broad Spectrum Antimicrobials Program led by BARDA. Recognizing the critical linkage to national bioterrorist preparedness, the Pandemic and All Hazards Preparedness Act of 2006 specifically identifies BARDA’s role in the development of broad spectrum antimicrobials.

    BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 available here.

    Anthrax Antimicrobials ASPR Awards BARDA Bioterrorism HHS
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDHS Science & Technology LRBAA
    Next Article NWRCE Funding for Biodefense Career Development

    Related Stories

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.